NASDAQ:SNGX - Soligenix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.05 +0.04 (+3.96 %)
(As of 11/20/2018 01:13 PM ET)
Previous Close$1.01
Today's Range$1.0101 - $1.0690
52-Week Range$0.91 - $3.70
Volume22,367 shs
Average Volume102,311 shs
Market Capitalization$18.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNGX
Previous Symbol
CUSIPN/A
Phone609-538-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio3.27
Quick Ratio3.27

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.43 million
Price / Sales3.19
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book1.46

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,140,000.00
Net Margins-146.45%
Return on Equity-185.54%
Return on Assets-104.14%

Miscellaneous

Employees18
Outstanding Shares16,520,000
Market Cap$18.17 million
OptionableNot Optionable

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.11). The biopharmaceutical company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.40 million. Soligenix had a negative return on equity of 185.54% and a negative net margin of 146.45%. View Soligenix's Earnings History.

When is Soligenix's next earnings date?

Soligenix is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for Soligenix.

What price target have analysts set for SNGX?

2 brokerages have issued 1 year price targets for Soligenix's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Soligenix's stock price to reach $3.50 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Soligenix.

What is the consensus analysts' recommendation for Soligenix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soligenix.

Has Soligenix been receiving favorable news coverage?

Media headlines about SNGX stock have been trending neutral on Tuesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Soligenix earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Soligenix's key competitors?

Who are Soligenix's key executives?

Soligenix's management team includes the folowing people:
  • Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 52)
  • Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 64)
  • Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 46)
  • Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 66)
  • Mr. Adam T. Rumage, VP of Project Management & Regulatory Affairs

Who are Soligenix's major shareholders?

Soligenix's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.61%) and Virtu Financial LLC (0.37%). Company insiders that own Soligenix stock include Christopher J Schaber, Marco Maria Brughera, Mark E Pearson, Randal J Kirk and Spa Essetifin. View Institutional Ownership Trends for Soligenix.

Which institutional investors are buying Soligenix stock?

SNGX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Marco Maria Brughera, Mark E Pearson and Spa Essetifin. View Insider Buying and Selling for Soligenix.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $1.05.

How big of a company is Soligenix?

Soligenix has a market capitalization of $18.17 million and generates $5.43 million in revenue each year. Soligenix employs 18 workers across the globe.

What is Soligenix's official website?

The official website for Soligenix is http://www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]


MarketBeat Community Rating for Soligenix (NASDAQ SNGX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  307
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel